Phaseline

Companies › Cellvax Therapeutics

Cellvax Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FK-PC101
Personalized cancer vaccine derived from patient's own prostate cancer tissue
–Phase 2Prostate Cancer (Adenocarcinoma)Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06636682FK-PC101Phase 2Prostate Cancer (Adenocarcinoma)OncologyFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Buzzard Pharmaceuticals Spectrum Pharmaceuticals Newish Technology (Beijing) BrainChild Bio TVAX Biomedical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.